A novel antibody combination of casirivimab and imdevimab gets positive feedback from the European Medicines Agency's- EMA for Medicinal Products for Human Use (CHMP) for the treatment of confirmed COVID-19 in patients who do not need supplemental oxygen and who are more prone to advancing to severe COVID-19, announced a renowned American biotechnology company on 26th February, 2021.

This antibody combination consists of two monoclonal antibodies specially formulated to obstruct infectivity of SARS-CoV-2.

The CHMP recommendation provides a coherent, European Union-level outlook concerning the overall effectiveness of this antibody mixture. This recmmendation will be helpful to the EU member states when making assessments concerning the possible use of the antibody mixture at a nationwide before the market approval. The CHMP assessed the existing data in non-hospitalized, COVID-19 patients along with supportive data from other settings.

To increase global supply of the antibody cocktail, the American biotechnology company has joined hands with a famous Swiss multinational healthcare company to ensure proper supply and distribution in the U.S. and outside. These organisations are dedicated to making this antibody mixture available to COVID-19 patients throughout the world in addition to access in low- and lower-middle-income nations in collaboration with public health organizations/non-profit organisations.